Latest Industry News & Trends

NurExone Reports Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

NurExone Biologic, with offices in Canada and Israel, reported Dec. 6 findings of a preclinical study of its lead candidate, ExoPTEN, for repairing optic nerve damage. Researchers utilized a rodent...

ViaLase Teams up with Moran Eye Center to Enhance Femto Laser Glaucoma Procedure

ViaLase of Aliso Viejo, California, reported Dec. 10 that it would partner with the John A. Moran Eye Center at the University of Utah to explore the effect of creating multiple channels in the tra...

Ophthalmologists Report 5.5 Percent Increase in Q3-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 5.5 percent in Q3-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

Bausch + Lomb Acquires Elios Vision, Developer of Excimer Laser Trabeculostomy

Bausch + Lomb announced Dec. 11 that an affiliate had acquired Elios Vision, developer of the Elios excimer laser trabeculostomy procedure for glaucoma. No financial details were disclosed. Elios’ ...

Konan Medical Launches ObjectiveField Perimeter in the US

Konan Medical has launched its ObjectiveField visual field analyzer in the US. The ObjectiveField is an objective perimeter designed to detect visual field abnormalities using pupillary responses. ...

2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Clinical Trial Updates for Ophthalmic Candidates, December 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees

The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...

MACs Finalize Coverage for Standalone and Combo MIGS Procedures

Five Medicare administrative contractors have issued their final coverage policies for minimally invasive glaucoma surgery, or MIGS, along with more technical billing and coding documents. The poli...

December 2024 Ophthalmic News Briefs

Dutch company Ophtec announced Nov. 18 that it had gained CE marking for its Artiplus phakic IOL. The company said the lens offered a solution for relatively young presbyopes, typically in their ea...

Bausch + Lomb Acquires Elios Vision, Developer of Excimer Laser Trabeculostomy

Bausch + Lomb announced Dec. 11 that an affiliate had acquired Elios Vision, developer of the Elios excimer laser trabeculostomy procedure for glaucoma. No financial details were disclosed. Elios’ ...

Konan Medical Launches ObjectiveField Perimeter in US

Konan Medical has launched its ObjectiveField visual field analyzer in the US. The ObjectiveField is an objective perimeter designed to detect visual field abnormalities using pupillary responses. ...

Avant, Ainnova Advancing Low-Cost Retinal Camera with AI Screening Software

Nevada-based Avant Technologies and Ainnova Tech, of Houston, Texas, announced Nov. 20 that the two companies would advance Ainnova’s proprietary low-cost retinal camera packaged with the Vision AI...

MACs Finalize Coverage for Standalone and Combo MIGS Procedures

Five Medicare administrative contractors have issued their final coverage policies for minimally invasive glaucoma surgery, or MIGS, along with more technical billing and coding documents. The poli...

Nicox Chooses Higher Dose of NCX 470 to Advance in Phase III Glaucoma Trials

France’s Nicox announced Nov. 19 that it had chosen the higher dose of NCX 470 ophthalmic solution to advance in the Phase III Mont Blanc trial in glaucoma. The company said both doses tested—0.065...

CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees

The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...

Harrow’s ImprimisRx Unit Gets $34.9 Million Trademark Infringement Verdict

Harrow’s ImprimisRx subsidiary received a $34.9 million verdict on Nov. 20, 2024, in a trademark infringement lawsuit against OSRX Pharmaceuticals, of Missoula, Montana. OSRX is an affiliate of Ocu...

Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering

EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...

Weighing the Ophthalmic Impact of Boom in GLP-1 Receptor Agonist Treatment

Recent studies indicate that up to 6 percent of the US population is currently taking a GLP-1 receptor agonist, a class of drugs prescribed to help manage blood glucose levels for diabetes and weig...

AAO and Eyecelerator Sessions Showcase Latest in Glaucoma Lasers and Surgical Devices

New glaucoma lasers and surgical devices were shown at various venues during the 2024 AAO meeting, including Glaucoma Subspecialty Day and the Eyecelerator meeting. There was also an important upda...

Clinical Trial Updates for Ophthalmic Candidates, November 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Emerging Companies Pursuing Ophthalmic Indications, November 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

Spinogenix Unveils Glaucoma Program to Evaluate Once-Daily Neuroprotective Pill

Los Angeles-based Spinogenix reported Oct. 16 that it was launching a program to evaluate SPG302 as a potential neuroprotective therapeutic for glaucoma. Spinogenix describes SPG302 as a once-a-day...

Nicox and Soleus Sign $16.5 Million Deal for Vyzulta Royalties, Equity Financing

France’s Nicox announced Oct. 14 a deal with Soleus Capital under which Soleus will acquire Nicox’ royalties from the glaucoma treatment Vyzulta for $15 million, while providing $1.5 million in equ...

AbbVie Withdraws EU Marketing Application for Durysta Implant for Glaucoma

Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...

Select US FDA Approvals and Clearances in September 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in September 2024, according to the agency’s database. Zeiss gained clearance for its combination Y...

ViaLase Releases Latest Glaucoma Laser Data at ESCRS Congress

Rick Lewis, MD, chief medical officer at ViaLase, provided an update at the 2024 ESCRS congress on the ViaLuxe glaucoma laser, including the system’s most recent clinical trial results. The ViaLuxe...

Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

October 2024 Ophthalmic News Briefs

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...

iCare Launches ST500 Slit Lamp Mounted Rebound Tonometer

Finland’s iCare, a subsidiary of Revenio Group, has launched its iCare ST500 rebound tonometer that can be attached to a slit lamp. The device gained US FDA 510(k) clearance on Sept. 27. The compan...

Iridex Appoints Patrick Mercer as Chief Executive Officer

Iridex reported Oct. 3 that it had appointed Patrick Mercer as chief executive officer, to go along with his role as president, effective Oct. 1. Mercer had also served as the company’s chief opera...

AbbVie Withdraws EU Marketing Application for Durysta

Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...

Nicox, Glaukos Sign Research and Option Agreement for Glaucoma Candidate

France’s Nicox announced Sept. 23 that it had signed an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5...

Ripple, AbbVie to Collaborate on Fully Biodegradable Bimatoprost Implant for Glaucoma

Ripple Therapeutics, of Toronto, Canada, announced Sept. 17 that it had signed a collaboration agreement with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral bimatop...

Ophthalmologists Report 0.5 Percent Increase in Q2-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 0.5 percent in Q2-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

Injectsense Reports First Human Implantation of Ultraminiature IOP Sensor

Injectsense, of Emeryville, California, announced Aug. 27 that it had implanted its first ultraminiature wireless sensor for measuring intraocular pressure (IOP). Glaucoma specialist Juan Mura, MD,...

Visiox to Merge with Ocuvex to Advance Two Ophthalmic Drug Candidates

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

September 2024 Ophthalmic News Briefs

Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...

Oculus Debuts Frequency Doubling Perimetry with Easyfield VR

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset, along with standard automated perimetry. The German ophthalmic diagnosti...

iStar Medical Appoints Richard Beckman, MD, as Chief Medical Officer

Belgium’s iStar Medical announced Sept. 4 that it had appointed Richard Beckman, MD, as chief medical officer and member of the company’s board. Beckman most recently served as CMO of Adverum Biote...

Injectsense Completes First Human Implantation of its Ultraminiaturized IOP Sensor

Injectsense, of Emeryville, California, announced Aug. 27 that it had implanted its first ultraminiature wireless sensor for measuring intraocular pressure (IOP). Glaucoma specialist Juan Mura, MD,...

Revenio’s iCare Subsidiary Acquires AI Screening Company Thirona Retina

Finland’s Revenio Group announced Aug. 20 that its iCare subsidiary had assumed ownership of the Dutch artificial intelligence (AI) software company Thirona Retina. iCare had made a minority invest...

Visiox to Merge with Ocuvex to Advance Candidates for Glaucoma, Postsurgical Pain and Inflammation

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

Steady Growth Expected in Single-Use Surgical Products, Even With Push to Cut OR Waste

Environmental sustainability programs have grown in scope over the last five years, with major ophthalmic surgery associations joining forces to propose specific actions to reduce the carbon footpr...

ViaLase Gains CE Marking for Femtosecond Laser for Glaucoma Treatment

ViaLase announced July 30 that the European Union had granted CE marking for its ViaLase Laser for the treatment of adults with primary open-angle glaucoma. The system uses an OCT-guided femtosecon...

Clinical Trial Updates for Ophthalmic Candidates, August 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

USC Alums Gift Eye Care Practice to Roski Eye Institute

Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...

Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex

AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....

Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint

Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...

USC Alums Gift Eye Care Practice to Roski Eye Institute

Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...

ViaLase Gains CE Marking for Femtosecond Laser for Glaucoma Treatment

ViaLase announced July 30 that the European Union had granted CE marking for its ViaLase Laser for the treatment of adults with primary open-angle glaucoma. The system uses an OCT-guided femtosecon...

Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...

Cancer Company TME Pharma Plans to Spin Off NOX-E36 for Eye Disease

Germany’s TME Pharma, a clinical-stage cancer company, announced July 22 that it planned to spin off its asset NOX-E36 to advance it for eye disease. NOX-E36 is an L-stereoisomer RNA aptamer inhibi...

Multitude of Novel Glaucoma Surgery Devices to Drive Procedure Growth

The goal of a growing number of companies entering the already crowded glaucoma device market is to provide surgical treatment options with greater safety and effectiveness. Thirty-six products are...

IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Certification for Marketing

Balance Ophthalmics has gained US FDA de novo classification for its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, a goggles and pump system designed to lower intraocular pressure (IOP) i...

Select US FDA Approvals and Clearances in June 2024

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in June 2024, according to the agency’s database. Alcon gained clearance for its much-anticipated ...

Emerging Companies Pursuing Ophthalmic Indications, July 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Nod for Marketing

Balance Ophthalmics has gained US FDA de novo classification for its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, a goggles and pump system designed to lower intraocular pressure (IOP) i...

Ophthalmologists Report 6 Percent Decline in Q1-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 6.0 percent in Q1-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity

Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...

Select US FDA Approvals and Clearances in May 2024

The US FDA granted six clearances through the ophthalmic device division using the 510(k) pathway in May 2024, according to the agency’s database. Reichert gained market clearance for its new hand-...

Surgeons, Societies Respond to MACs’ New Proposed MIGS Limits

Surgeons and ophthalmic societies worked together at open meetings in June to address five Medicare administrative contractors’ latest proposal to limit coverage of minimally invasive glaucoma surg...

Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer

Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...

June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity

Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...

Nidek Launches RS-1 Glauvas OCT System

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas optical coherence tomography (OCT) system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlin...

MACs Propose New Limits on MIGS Procedures

Five Medicare administrative contractors have proposed new limits to their coverage of minimally invasive glaucoma surgery (MIGS). The move comes a year after the same MACs roiled the glaucoma subs...

Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen

AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...

New World Medical Gains US 510(k) Clearance for KDB Glide

New World Medical reported May 22 that its Kahook Dual Blade Glide (KDB Glide) had gained US FDA 510(k) clearance. The KDB Glide was previously classified as a Class 1, 510(k)-exempt device. With t...

Reichert Launches Tono-Vera Hand-held Tonometer in US

Reichert announced May 6 that its Tono-Vera hand-held tonometer is now available in the US. Tono-Vera provides quick, automated, and reliable intraocular pressure measurements with rebound tonomete...

Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering

RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...

Emerging Companies Pursuing Ophthalmic Indications, May 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Artificial Intelligence Takes Leading Role at 2024 ARVO Meeting

Artificial intelligence was a prominent topic at the 2024 ARVO meeting. Discussions ranged from using AI in published ophthalmic research to employing it in early detection and monitoring of eye di...

2024 ARVO Awards Highlight New Focus on Inflammation

The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...

Clinical Trial Updates for Ophthalmic Candidates, May 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case

Sight Sciences, of Menlo Park, California, reported April 29 that it had received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, file...

May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...

First-in-Human Study for Injectsense Implantable IOP Monitor Approved by Chilean Clinic

Injectsense announced May 6 that the ethics committee at the Centro de la Vision Clinic in Santiago, Chile, has approved a 20-patient study of the company’s ultra-miniature wireless sensor, designe...

Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird

Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...

Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case

Sight Sciences, of Menlo Park, California, reported April 29 that ithad received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, filed...

Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox

Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...

Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research

The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...

Second Shake-up May be Underway in the Glaucoma Pharmaceuticals Market

Allergan and Novartis replaced Merck and Pfizer at the top of the glaucoma pharmaceuticals market a decade ago. Now it could be their turn to pass the baton. Allergan, acquired by AbbVie in 2020 an...

iDose, Eylea HD, Izervay Get J-Codes for Billing Payers in the US

The Centers for Medicare and Medicaid Services (CMS) has issued J-codes for Glaukos’ iDose, Regeneron’s Eylea HD, and Astellas Pharma’s Izervay. The code for iDose takes effect July 1, 2024, while ...

Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

Study Attempts to Clarify Best Fit for Vyzulta

Constance Okeke, MD, is helping to clear the confusion that can come from having multiple choices. “There are so many medicines coming into glaucoma that it can be difficult for a clinician to know...

Generic Drugmakers Sued by Large Employers in Price Fixing Scheme

Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...

Clinical Trial Updates for Ophthalmic Candidates , April 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme

Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...

LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis

Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...

Glaukos’ iDose Gets J-Code for Medical Billing in the US

The Centers for Medicare and Medicaid Services (CMS) has issued a J-code for Glaukos’ iDose. The billing code takes effect July 1, 2024. iDose TR gained US FDA approval under the 505(b)(2) pathway ...

Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer

France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...

2023 Ophthalmic Revenue Roundup for Iridex and NovaBay

Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...

Ophthalmologists Report 1.8 Percent Decline in Q4-2023 Procedure Volume

----- Refractive: -12.1 IOL: 5.4 Glaucoma: 4.8 Retina: -4.4 ----- US ophthalmologists reported that ophthalmic procedures decreased 1.8 percent in Q4-2023 compared with the same quarter in 2022, ac...

CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US

Israel-based CorNeat Vision announced Feb. 27 that it had launched its EverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first syn...

Select US FDA Approvals and Clearances in February 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in February 2024, according to the agency’s database. CATS Tonometer received clearance for its ton...

Celanese Announces Launch of Glaukos’ iDose TR Travoprost Implant

Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a specialty materials and chemical company based in Dallas, Texas, prod...

Clinical Trial Updates for Ophthalmic Candidates, March 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Emerging Companies Pursuing Ophthalmic Indications, March 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix

Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...

Celanese Announces Commercial Launch of Glaukos’ iDose TR Travoprost Implant

Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a global specialty materials and chemical company based in Dallas, Texa...

2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus

Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...

CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US

Israel-based CorNeat Vision announced Feb. 27 that it had launched itsEverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first synt...

Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease

Innovative diagnostics for glaucoma screening, staging, and management were a highlight of the Glaucoma 360 New Horizons Forum, with several physicians showcasing new approaches to visual field tes...

Sight Sciences Reports Launching of Omni Ergo-Series for Canaloplasty in Europe at ESCRS Winter Meeting

Sight Sciences announced Feb. 14 that it would launch the Ergo-Series of its Omni system for canaloplasty in Europe at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meetin...

Select US FDA Approvals and Clearances in January 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in January 2024, according to the agency’s database. Meridian received clearance for three laser mo...

4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering

4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...

Participation in the 2024 Glaucoma 360 Attendee Survey Hits All-Time High

Ophthalmologist (MD) and optometrist (OD) attendees of the 2024 Glaucoma 360 (G360) meeting demonstrated a record interest in participating in the Ninth Annual G360 Survey powered by Market Scope. ...

Top Innovators Delve into Latest Concepts at G360’s New Horizons Forum

Two of ophthalmology’s leading innovators headlined the New Horizons Forum at the Glaucoma 360 meeting. Sean Ianchulev, MD—arguably the most prolific ophthalmic product inventor in the US—led off t...

Reimbursement Issues for Glaucoma Surgery Remain Threat, G360 Speakers Say

Attendees of the G360 New Horizons Forum received a detailed breakdown of the battle that the ophthalmic industry collectively waged throughout 2023 to stop proposed limits to Medicare coverage for...

Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84

Glaucoma specialist H. Dunbar Hoskins Jr., MD, a longtime executive of the American Academy of Ophthalmology who helped shape the society, died Jan. 27, the AAO reported. Hoskins was 84. He served ...

Emerging Companies Pursuing Ophthalmic Indications, February 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

Nicox Licenses NCX 470 (Bimatoprost) Drop for Glaucoma to Kowa for Japan for $3.2 Million Up Front

France’s Nicox announced Feb. 8 that it had signed a deal granting Japanese drug company Kowa exclusive Japanese rights to develop and commercialize Nicox’ NCX 470 (0.1% bimatoprost) eye drop for g...

Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84

Glaucoma specialist H. Dunbar Hoskins Jr., MD, a longtime executive of the American Academy of Ophthalmology who helped shape the society, died Jan. 27, the AAO reported. Hoskins was 84. He served ...

2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox

Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....

Belkin Vision’s Eagle Laser for Glaucoma Receives FDA 510(k) Clearance

Israeli company Belkin Vision reported Dec. 12 that its Eagle laser for glaucoma had gained US FDA 510(k) clearance. The Eagle is intended for use in performing a new automated, noncontact, one-sec...

US FDA Approves iDose TR (Travoprost Implant) from Glaukos for Glaucoma

Glaukos reported Dec. 14 that the US FDA had approved its new drug application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, indicated for the reduction ...

Clinical Trial Updates for Ophthalmic Candidates, January 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

2023 in Review: MAC Turmoil Shifts Landscape for Canal-Based Glaucoma Devices

Medicare administrative contractors (MACs) threw the near-term future of the glaucoma device market into turmoil in early 2023 when they challenged the medical necessity of canal-based surgical pro...

January 2024 Ophthalmic News Briefs

Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...

New Iridex 532 and Iridex 577 Lasers Launched in US Market

Iridex announced Jan. 11 the US launch of its next-generation Iridex 532 green and Iridex 577 yellow lasers for retina and glaucoma. Iridex, of Mountain View, California, said both lasers include c...

US MACs Retire Coverage Policies That Would Have Limited Some MIGS Procedures

Five Medicare administrative contractors (MACs) have withdrawn and retired final policies that would have stopped Medicare coverage of common minimally invasive glaucoma surgeries in their US juris...

Ophthalmic Drugmaker Visiox to Merge with SPAC to Gain Nasdaq Listing

Privately held Visiox Pharmaceuticals reported Dec. 27 that it will gain a listing on the Nasdaq through a merger with PowerUp Acquisition Corp., a special purpose acquisition company (SPAC) based ...

iHealthScreen Gains UK Approval for iPredict AI Screener for DR, AMD, and Glaucoma

New York-based iHealthScreen announced Dec. 5 that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had approved its iPredict automated AI screening system for early diagnosis of d...

Belkin Vision’s Eagle Laser Receives FDA 510(k) Clearance

Israeli company Belkin Vision reported Dec. 12 that its Eagle laser for glaucoma had gained US FDA 510(k) clearance. The Eagle is intended for use in performing a new automated, noncontact, one-sec...

US FDA Approves iDose TR (Travoprost Implant) from Glaukos for Glaucoma

Glaukos reported Dec. 14 that the US FDA had approved its new drug application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, indicated for the reduction ...

Ophthalmologists Report 6.4 Percent Decline in Q3-2023 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 6.4 percent in Q3-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...

AAO Glaucoma Day Session Evaluates Latest Devices Advancing or Sold Outside the US

US glaucoma specialists have over 20 surgical options to treat their patients, but even more devices are available or in the pipeline outside the US, and their developers could seek FDA approval. M...

Ophthalmic Company Revenue Increases 3.4 Percent in Third Quarter of 2023

Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...

Emerging Companies Pursuing Ophthalmic Indications, December 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Clinical Trial Updates for Ophthalmic Candidates, December 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More

2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...

December 2023 Ophthalmic News Briefs

Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...

France’s Ciliatech Unveils New Design of CID Glaucoma Surgical Device

France’s Ciliatech revealed on Dec. 5 a new design of its CID (Cilioscleral Interpositioning Device), following the filing of additional patents. Ciliatech says its approach with the CID avoids the...

SpyGlass Pharma Appoints Margot Goodkin, MD, PhD, as Chief Medical Officer

SpyGlass Pharma announced Dec. 5 that it had appointed Margot Goodkin, MD, PhD, as chief medical officer. Goodkin is a glaucoma fellowship-trained ophthalmologist and biopharmaceutical industry vet...

Santen Receives EU Approval for Catiolanze (Preservative-Free Latanoprost) in Glaucoma

Japanese drugmaker Santen Pharmaceutical announced Nov. 17 that the European Commission had approved its marketing authorization application for preservative-free Catiolanze (cationic emulsion of l...

EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A

EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...

Select US FDA Approvals and Clearances in October 2023

The US FDA granted five clearances through the ophthalmic device division using the 510(k) pathway in October 2023, according to the agency’s database. Heidelberg gained market clearance for its An...

Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos

Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...

Clinical Trial Updates for Ophthalmic Candidates, November 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Buzzworthy Topics at the 2023 AAO Meeting

Dry Eye: New products kept generating buzz around dry eye. Bausch + Lomb leaned into the promotion of Miebo, the new, first-in-class drug therapy that directly targets tear evaporation. Diagnostic ...

Eyecelerator at AAO Showcases Innovators and Awards $45 Thousand in Prize Money

Eyecelerator awarded a total of $45 thousand in prize money to winning pitch challengers at its fall meeting, after emerging companies got a chance to work with accomplished industry veterans to re...

Diagnostic Leaders Showcase Devices, Collaborations at AAO Meeting

Notable diagnostic innovations showcased at the 2023 meeting of the American Academy of Ophthalmology were Topcon’s Tempo perimeter and Heidelberg Engineering’s Anterion anterior OCT platform. Also...

Five MACs Finalize Plans to Curb Coverage of Non-stent Glaucoma Procedures

Five of the seven Medicare administrative contractors (MACs) in the US have issued their final reimbursement plans for minimally invasive glaucoma surgery (MIGS) procedures, confirming that they wo...

Emerging Companies Pursuing Ophthalmic Indications, November 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

November 2023 Ophthalmic News Briefs

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...

Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix

Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...

Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Five Others

Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...

Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox

Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...

Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos

Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...

Buzzworthy Topics at the 2023 ESCRS Congress

Minimally Invasive Glaucoma Surgery (MIGS): The ESCRS highlighted the growing importance of MIGS this year by holding the meeting’s first MIGS master class. Several speakers in other sessions extol...

Ophthalmic Laser Companies Look to Improve on Convenience, Experience

The therapeutic ophthalmic laser market will experience modest growth in the next five years, as laser manufacturers focus on improving convenience and experience for ophthalmologists and patients....

Emerging Companies Pursuing Ophthalmic Indications, October 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Sight Sciences to Cut 25 Employees as it Awaits MACs’ Coverage Decision

Sight Sciences, of Menlo Park, California, has informed its employees that it will cut its workforce of 250 by 25 employees as it awaits a final decision by five of the seven Medicare Administrativ...

Padagis Launches Generic Brinzolamide Drop for Glaucoma

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis with offices in the US and Israel...

Théa Launches Preservative-Free Iyuzeh (Latanoprost) for Glaucoma in the US

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

Mati Completes Facility to Manufacture Evolute Punctal Plug Portfolio

Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...

Ophthalmologists Report 4.9 Percent Decrease in Q2-2023 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 4.9 percent in Q2-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...

Laser Company Iridex to Undergo Strategic Review

Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor. The Mountain View, California, ophthalmic laser company said there...

Select US FDA Approvals and Clearances in August 2023

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in August 2023, according to the agency’s database. RxSight received clearance for a new IOL injec...

FDA Warns Eight Companies Over Marketing Unapproved or Unsafe Eye Drops in the US

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

Ophthalmic Diagnostic Equipment Market To Grow 3.8 Percent Through 2028, Driven by OCT Systems

Market Scope estimates that the ophthalmic diagnostic equipment market will generate $3.7 billion in total revenue in 2023, and the market will grow to $4.4 billion by 2028, for a compound annual g...

Clinical Trial Updates for Ophthalmic Candidates, September 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Apotex Launches Brimonidine Tartrate 0.1% Ophthalmic Solution in US

Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...

Weekly Surgeon Poll, September 2023

FDA Warns Eight Companies Over Marketing Unapproved Eye Drops

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

Neurotech Adds Alex Gorsky to its Board as Lead Director

Neurotech Pharmaceuticals reported Sept. 13 that Alex Gorsky had been elected to its board as lead director. Gorsky, former chairman and chief executive officer of Johnson & Johnson, stepped down f...

Apotex Launches Brimonidine Tartrate 0.1% Ophthalmic Solution in US

Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...

Iridex to Undergo Strategic Review

Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor for the process. The Mountain View, California, ophthalmic laser co...

Tarsier’s Dazdotuftide Misses Phase III Primary Endpoint, Shows Promise for Uveitic Glaucoma

Israel’s Tarsier Pharma reported Aug. 23 that its TRS01 (dazdotuftide) eye drops failed to meet the primary inflammation endpoint in a Phase III trial in patients with active noninfectious anterior...

Clinical Trial Updates for Ophthalmic Candidates, August 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees

The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...

US FDA Target Action Dates for Ophthalmic Drug Candidates, August to December 2023

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

August 2023 Ophthalmic News Briefs

New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...

Q2-2023 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, and Two Others

Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...

CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees

The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...